Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for AnaptysBio, Inc. (ANAB : NSDQ)

• Company Description    AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. Number of Employees: 104

• Price / Volume Information    Yesterday's Closing Price: $59.71 Daily Weekly Monthly 20 Day Moving Average: 678,066 shares Shares Outstanding: 29.10 (millions) Market Capitalization: $1,737.62 (millions) Beta: 0.79 52 Week High: $72.36 52 Week Low: $11.58 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 16.46% 10.77% 12 Week 6.42% -1.62% Year To Date 23.16% 14.56%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10770 WATERIDGE CIRCLE SUITE 210 - SAN DIEGO,CA 92121 USA ph: 858-362-6295 fax: - investors@anaptysbio.com http://www.anaptysbio.com

• General Corporate Information    Officers Daniel Faga - President; Chief Executive Officer and Director Dennis Mulroy - Chief Financial Officer Dennis Fenton - Director Rita Jain - Director Magda Marquet - Director Peer Information AnaptysBio, Inc. (CORR.) AnaptysBio, Inc. (RSPI) AnaptysBio, Inc. (CGXP) AnaptysBio, Inc. (BGEN) AnaptysBio, Inc. (GTBP) AnaptysBio, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 032724106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/05/26 Share - Related Items Shares Outstanding: 29.10 Most Recent Split Date: (:1) Beta: 0.79 Market Capitalization: $1,737.62 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.32 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.80 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: 04/20/2026 - $22.51 Next EPS Report Date: 08/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 136.31 Price/Cash Flow: - Price / Sales: 7.48 EPS Growth vs. Year Ago Period: -43.75% vs. Previous Quarter: -216.46% Sales Growth vs. Year Ago Period: -7.98% vs. Previous Quarter: -76.39% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - -1,101.24 ROA 03/31/26 - -7.75 12/31/25 - -3.59 09/30/25 - -21.23 Current Ratio 03/31/26 - 7.58 12/31/25 - 9.07 09/30/25 - 8.68 Quick Ratio 03/31/26 - 7.58 12/31/25 - 9.07 09/30/25 - 8.68 Operating Margin 03/31/26 - -11.53 12/31/25 - -5.64 09/30/25 - -49.94 Net Margin 03/31/26 - -11.53 12/31/25 - -5.64 09/30/25 - -49.94 Pre-Tax Margin 03/31/26 - -11.46 12/31/25 - -5.57 09/30/25 - -49.89 Book Value 03/31/26 - 0.44 12/31/25 - 1.34 09/30/25 - -1.06 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - - Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - -

Powered by Zacks Investment Research ©